{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:30Z","timestamp":1791251790449,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0068976","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T21:00:03Z","timestamp":1374094803000},"page":"e68976","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001\u20132011"],"prefix":"10.1371","volume":"8","author":[{"given":"Bruce","family":"Guthrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Reynish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,7,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review","volume":"50","author":"S Dusetzina","year":"2012","journal-title":"Medical Care"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/11596950-000000000-00000","article-title":"Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals: Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008","volume":"35","author":"R Ruiter","year":"2012","journal-title":"Drug Saf"},{"key":"ref3","unstructured":"Committee on Safety of Medicines (2004) Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. London: Committee on Safety of Medicines."},{"key":"ref4","unstructured":"NHS National Prescribing Centre (2009) Important updates on drug safety from the MHRA\/CHM."},{"key":"ref5","unstructured":"Committee for Medicinal Products for Human Use (2008) Opinion of the Committee for Medicinal Products for Human Use pursuant to article 5(3) of regulation (EC) No 726\/2004 on conventional antipsychotics. Brussels: European Medicines Agency."},{"key":"ref6","unstructured":"US Department of Health and Human Services (2005) Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Food and Drug Administration Web site. Available: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm053171.htm<\/ext-link>. Accessed 2012 Jun 21."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ageing\/afq090","article-title":"The burden of psychotropic drug prescribing in people with dementia: a population database study","volume":"39","author":"B Guthrie","year":"2010","journal-title":"Age Ageing"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archgenpsychiatry.2010.200","article-title":"Trends in Antipsychotic Use in Dementia 1999\u20132007","volume":"68","author":"HC Kales","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials","volume":"294","author":"LS Schneider","year":"2005","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic Drug Use and Mortality in Older Adults with Dementia","volume":"146","author":"SS Gill","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1503\/cmaj.061250","article-title":"Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients","volume":"176","author":"S Schneeweiss","year":"2007","journal-title":"Canadian Medical Association Journal"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archinte.168.10.1090","article-title":"Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia","volume":"168","author":"PA Rochon","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"ref13","unstructured":"Banerjee S (2009) The use of antipsychotic medication for people with dementia: Time for action. London: Department of Health."},{"key":"ref14","first-page":"e76","article-title":"A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial) PLoS Medicine","volume":"5","author":"C Ballard","year":"2008"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"C Ballard","year":"2009","journal-title":"The Lancet Neurology"},{"key":"ref16","unstructured":"Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines (2009) Antipsychotics: use in elderly people with dementia."},{"key":"ref17","unstructured":"Department of Health (2009) Living well with dementia: A National Dementia Strategy. London: Department of Health."},{"key":"ref18","unstructured":"Department of Health (2009) Government response to Professor Sube Banerjee\u2019s report on the prescribing of anti-psychotic drugs to people with dementia. London: Department of Health."},{"key":"ref19","unstructured":"NHS England: Primary Care Commissioning (2009) QOF Implementation: Business Rules."},{"key":"ref20","unstructured":"Information Services Division NHS Scotland (2008) Measuring Long-Term Conditions in Scotland. Edinburgh: ISD Scotland. Available: http:\/\/www.isdscotland.org\/isd\/5658.html<\/ext-link>."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"A Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.3399\/bjgp11X593848","article-title":"Trends in primary care antidepressant prescribing 1995\u20132007: a longitudinal population database analysis","volume":"61","author":"P Lockhart","year":"2011","journal-title":"British Journal of General Practice"},{"key":"ref23","unstructured":"Alzheimer\u2019s Society, Alzheimer Scotland, Action on Dementia (2012) Mapping the Dementia Gap 2011: Progress on improving diagnosis of dementia 2010\u20132011."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euroneuro.2005.04.003","article-title":"Prevalence of dementia in the elderly in Europe","volume":"15","author":"C Berr","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1503\/cmaj.071540","article-title":"Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis","volume":"179","author":"E Valiyeva","year":"2008","journal-title":"Canadian Medical Association Journal"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","article-title":"Impact of FDA Black Box Advisory on Antipsychotic Medication Use","volume":"170","author":"E Dorsey","year":"2010","journal-title":"Archives of Internal Medicine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/ps.2008.59.5.547","article-title":"Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996\u20132006","volume":"59","author":"S Alessi-Severini","year":"2008","journal-title":"Psychiatric Services"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1176\/ajp.2007.164.6.884","article-title":"Decline in Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality With SSRIs","volume":"884\u2013891","author":"A Libby","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1503\/cmaj.071265","article-title":"Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults","volume":"178","author":"LY Katz","year":"2008","journal-title":"Canadian Medical Association Journal"},{"key":"ref30","unstructured":"The Information Centre for Health and Social Care (2012) National Dementia and Antipsychotic Prescribing Audit. Leeds: NHS England. Available: http:\/\/www.ic.nhs.uk\/services\/national-clinical-audit-support-programme-ncasp\/national-dementia-and-antipsychotic-prescribing-audit<\/ext-link>."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneurol.2009.39","article-title":"Management of agitation and aggression associated with Alzheimer disease","volume":"5","author":"CG Ballard","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"ref32","unstructured":"MHRA (2009) Monthly lists of letters for healthcare professionals on the safety of medicines. London: Medicines and Healthcare products Regulatory Agency. Available: http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines\/index.htm<\/ext-link>. Accessed 2012 Aug."},{"key":"ref33","unstructured":"MHRA (2009) Children\u2019s over-the-counter cough and cold medicines: New advice. London: Medicines and Healthcare products Regulatory Agency. Available: http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/CON038908<\/ext-link>. Accessed 2012 Aug."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0068976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T16:20:43Z","timestamp":1540311643000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0068976"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,17]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0068976","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,17]]}}}